Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. (NASDAQ: QURE) is a gene therapy company that regularly issues news on its clinical programs, regulatory interactions, and financing activities. The company describes itself as delivering single‑treatment gene therapies with potentially curative results and has reported that the approvals of its gene therapy for hemophilia B mark a major milestone in genomic medicine. News about uniQure often highlights progress in its pipeline for Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
A major focus of QURE news coverage is AMT‑130, uniQure’s investigational gene therapy for Huntington’s disease. Press releases and related SEC filings detail pivotal Phase I/II trial results, including statistically significant slowing of disease progression at 36 months in high‑dose cohorts compared to a propensity score‑matched external control, as well as trends in motor and cognitive endpoints and biomarker changes. Investors also see updates on the company’s regulatory dialogue with the U.S. Food and Drug Administration, including pre‑BLA and Type A meetings and feedback on the adequacy of Phase I/II data for a potential Biologics License Application.
Beyond AMT‑130, uniQure news includes early‑stage data and enrollment updates for AMT‑260 in refractory mesial temporal lobe epilepsy, AMT‑191 in Fabry disease, and AMT‑162 in SOD1 ALS. Corporate news items cover public offerings of ordinary shares and pre‑funded warrants, amendments to loan facilities, and quarterly financial results. This QURE news page aggregates such disclosures so readers can follow clinical milestones, regulatory developments, and capital markets events that shape uniQure’s gene therapy business over time.
uniQure N.V. has appointed Leonard E. Post, Ph.D., to its Board of Directors, enhancing its research leadership. Dr. Post, with over 35 years in biotechnology, will also chair the Research & Development Committee. His past roles include significant positions at BioMarin and Onyx Pharmaceuticals, focusing on gene therapy. This strategic move aims to bolster uniQure's pipeline, particularly in preparing for marketing authorization of etranacogene dezaparvovec for hemophilia B. This leadership change reflects a commitment to advancing innovative therapies for severe medical conditions.
uniQure N.V. (NASDAQ: QURE) announced a virtual format for its 2020 Annual General Meeting on June 17, 2020, due to COVID-19 concerns. Shareholders of record as of May 20, 2020, can participate via a virtual meeting platform but cannot vote in real-time or attend in person. The meeting’s details can be accessed through the uniQure website. The company is focused on advancing gene therapy treatments for severe genetic diseases, including hemophilia and Huntington’s disease.
Summary not available.
Summary not available.